New CEO Dodd Up For The Task Of Turning Around Aeterna Zentaris
This article was originally published in The Pink Sheet Daily
Executive Summary
David Dodd assumed the role of chief executive at the Canadian oncology company in April and has clear plans to create a revenue stream that will help finance its portfolio of oncology candidates.
You may also be interested in...
Keryx Share Price Tumbles Sharply On Phase III Failure Of Perifosine
With disappointing data in advanced colorectal cancer, Keryx is expected to abandon development of the Akt pathway inhibitor and focus all efforts on Phase III candidate Zerenex in ESRD.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.